Serotiny

Serotiny is designing new genes for next-generation cell and gene therapies. Using synthetic biology approaches, Serotiny is focusing on three platforms: invention of new therapeutic genes, engineering of therapeutic multi-domain proteins and tuning of a cell’s therapeutic properties for complex contexts such as cell killing in a tumor microenvironment. The core of Serotiny’s platform is the coupling of intelligent protein design software with innovative high-throughput assays, enabling them to discover novel cell therapies at an unprecedented scale. Most recently, Serotiny was acquired by Johnson & Johnson.

Jobs: